Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

ELAN - Elanco Animal Health Incorporated... | Finranks

Home

/

ELAN

E

Elanco Animal Health Incorporated (ELAN)

NYQ – Цена в реальном времени. Валюта: USD

21.81

-0.92 (-4.05%)

Рынок открыт: Aug 12, 2026, 11:42 AM EDT

22.73

0.00 (0.00%)

Предыдущая сессия: Aug 11, 2026, 7:46 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform

Elanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform

Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN's innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program and strong cash flow; net leverage is targeted below 3.0x by 2027.

Elanco Animal Health Q2 Earnings Call Highlights

Elanco Animal Health Q2 Earnings Call Highlights

Elanco Animal Health NYSE: ELAN reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth.

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also offers producers Negasunt® Powder (coumaphos, propoxur, and sulfanilamide topical powder) and Tanidil®, which received emergency authorizations earlier this year, as well as EPA-registered Catron™ IV.

Elanco CEO on Boosted Forecast, Surge in Tick Bites

Elanco CEO on Boosted Forecast, Surge in Tick Bites

Elanco Animal Health President and CEO Jeff Simmons discusses what's behind the company's increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent surge in tick bites and consumer spending on pet health products.

ADUS vs. ELAN: Which Stock Is the Better Value Option?

ADUS vs. ELAN: Which Stock Is the Better Value Option?

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Addus HomeCare (ADUS) and Elanco Animal Health Incorporated (ELAN). But which of these two stocks offers value investors a better bang for their buck right now?

Elanco Animal Health Incorporated (ELAN) Q2 2026 Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) Q2 2026 Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) Q2 2026 Earnings Call Transcript

Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products

Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products

Elanco Animal Health Incorporated (NYSE:ELAN) delivered strong financial performance for the second quarter of 2026, driven by robust demand across its Pet Health portfolio and expanding margins.

Видео

Elanco CEO on Boosted Forecast, Surge in Tick Bites

Пресс-релизы

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also offers producers Negasunt® Powder (coumaphos, propoxur, and sulfanilamide topical powder) and Tanidil®, which received emergency authorizations earlier this year, as well as EPA-registered Catron™ IV.

Elanco Animal Health Reports Second Quarter 2026 Results

Elanco Animal Health Reports Second Quarter 2026 Results

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% organic constant currency growth Reported Net Income of $54 million, Adjusted Net Income of $174 million Adjusted EBITDA of $288 million; Adjusted EBITDA Margin of 21.2% Reported EPS of $0.11, Adjusted EPS of $0.34 Net leverage ratio of 3.1x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.25 billion Raising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth Raising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-over-year increase of 13% at midpoint Raising Adjusted EPS to $1.10 to $1.16, a year-over-year increase of 20% at midpoint Improving year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA INDIANAPOLIS, Aug. 5, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2026, provided guidance for the third quarter of 2026, and updated guidance for the full year 2026. "Elanco's second quarter results demonstrate our momentum and leadership in the attractive animal health industry," stated Jeff Simmons, President and CEO of Elanco.